Gnubiotics Sciences bags CHF 2.6 million

Please login or
register
30.07.2020
Gnubiotics Team

Vaud based Gnubiotics Sciences is revolutionising microbiome health in humans and animals. The startup has secured CHF 2.6 million in a Series A1 round, which included current shareholders and new investors.

Founded in 2016, Gnubiotics Sciences SA is developing a platform to commercialise microbiome modulating products for the functional and medical nutrition markets with a new category of complex molecules: glycans. Gnubiotics’ unique and proprietary technology platform combines the power of chemistry and genomics to develop glycans that are proving to have unparalleled efficacy in restoring microbiome equilibrium, enabling the host to harness its power.

Its first pipeline candidate, AMObiome is an animal milk oligosaccharide biosimilar. AMObiome is to be used as nutritional support for microbiome diversity and crucial for life-long gut health of animals. To accelerate its commercialisation activities, the company has secured fresh capital from existing shareholders and new investors.

In parallel to its series A1 round, Gnubiotics has also secured a CHF 787’000 loan from UBS backed by the Canton de Vaud and Swiss Confederation. With this new round of funding and loan, Gnubiotics’ total funds raised add up to CHF 9.5 million.

(Press release/RAN)

0Comments

More news about

Gnubiotics Sciences SA

Company profiles on startup.ch

Gnubiotics Sciences SA

rss